Nanotech-Highflyer FLML Kursziel 43 Dollar !!! - 500 Beiträge pro Seite
eröffnet am 28.08.03 18:23:36 von
neuester Beitrag 12.03.04 19:58:31 von
neuester Beitrag 12.03.04 19:58:31 von
Beiträge: 6
ID: 769.544
ID: 769.544
Aufrufe heute: 0
Gesamt: 1.989
Gesamt: 1.989
Aktive User: 0
ISIN: US3384881096 · WKN: 901606
0,0000
EUR
0,00 %
0,0000 EUR
Letzter Kurs Lang & Schwarz
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5800 | +54,90 | |
| 0,7000 | +16,67 | |
| 1,9380 | +16,33 | |
| 1,5000 | +16,28 | |
| 14,390 | +15,12 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 160,90 | -14,14 | |
| 16,100 | -15,26 | |
| 4,0000 | -20,00 | |
| 0,7500 | -35,34 | |
| 2,1000 | -47,50 |
Feedback
Nach den Mega-News von gestern werden jetzt die Kursziele angehoben!
11:08AM Flamel target raised to $43 at Merriman (FLML) 27.80 +0.85: Merriman Curhan Ford reiterates their Buy rating and increases their target to $43 from $30; firm believes that the co`s established relationships with Biovail, GlaxoSmithKline, Bristol Meyers, and Merck as well as the large number of patent expirations expected on major blockbuster drugs provide FLML with enormous growth potential going forward.
Es ist wirklich sehr beeindruckend, wie extrem positiv sich das Unternehmen entwickelt.
Da fallen mir die Worte aus einer Kolumne hier ein: Ein Nanostock auf dem Weg zum "Big Player" - genau so schauts aus!!!
Grüße...
Isonics
11:08AM Flamel target raised to $43 at Merriman (FLML) 27.80 +0.85: Merriman Curhan Ford reiterates their Buy rating and increases their target to $43 from $30; firm believes that the co`s established relationships with Biovail, GlaxoSmithKline, Bristol Meyers, and Merck as well as the large number of patent expirations expected on major blockbuster drugs provide FLML with enormous growth potential going forward.
Es ist wirklich sehr beeindruckend, wie extrem positiv sich das Unternehmen entwickelt.
Da fallen mir die Worte aus einer Kolumne hier ein: Ein Nanostock auf dem Weg zum "Big Player" - genau so schauts aus!!!
Grüße...
Isonics
Hier noch mal die entsprechende W : O - Kolumne zu Flamel:
http://www.wallstreet-online.de/ws/news/news/main.php?&m=3&a…
http://www.wallstreet-online.de/ws/news/news/main.php?&m=3&a…
http://www.hoovers.com/flamel-technologies/--ID__51434,ticke…
Ist wirklich interessant!
Was sagt Ihr dazu?
Ist wirklich interessant!
Was sagt Ihr dazu?
Das kam gestern nachbörslich.
Flamel Technologies Announces Receipt of Milestone Payment from GlaxoSmithKline
Monday January 5, 4:23 pm ET
LYON, France--(BUSINESS WIRE)--Jan. 5, 2004--Flamel Technologies S.A. (Nasdaq:FLML - News) today announced that GlaxoSmithKline and Flamel have determined that Flamel has met the technical success requirements necessary to trigger the payment of a $2 million milestone in respect of the license agreement between the companies for the application of Flamel`s Micropump® technology.
"We are pleased with this recent medical success with a formulation for a major in-line product using our Micropump® technology," said Dr. Gerard Soula, president and chief executive officer of Flamel Technologies, S.A. "We are excited to continue our collaboration with GSK."
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste- masking technology for the oral administration of small molecule drugs. Flamel`s Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins.
For further information on the Company, please review Flamel`s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2002.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management`s current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. Among other risks, there can be no guarantee that the product described in this release will receive regulatory approval, or that it will prove to be commercially successful. This and other risk factors are discussed in the company`s 2002 Annual Report on Form 10-K and in the company`s periodic reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Contact:
Flamel Technologies S.A.
Dr. Gerard Soula, 33-4-72-78-34-34
soula@flamel.com
or
Stephen H. Willard, 202-862-8400
willard@flamel.com
--------------------------------------------------------------------------------
Source: Flamel Technologies S.A.
Flamel Technologies Announces Receipt of Milestone Payment from GlaxoSmithKline
Monday January 5, 4:23 pm ET
LYON, France--(BUSINESS WIRE)--Jan. 5, 2004--Flamel Technologies S.A. (Nasdaq:FLML - News) today announced that GlaxoSmithKline and Flamel have determined that Flamel has met the technical success requirements necessary to trigger the payment of a $2 million milestone in respect of the license agreement between the companies for the application of Flamel`s Micropump® technology.
"We are pleased with this recent medical success with a formulation for a major in-line product using our Micropump® technology," said Dr. Gerard Soula, president and chief executive officer of Flamel Technologies, S.A. "We are excited to continue our collaboration with GSK."
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste- masking technology for the oral administration of small molecule drugs. Flamel`s Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins.
For further information on the Company, please review Flamel`s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2002.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management`s current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. Among other risks, there can be no guarantee that the product described in this release will receive regulatory approval, or that it will prove to be commercially successful. This and other risk factors are discussed in the company`s 2002 Annual Report on Form 10-K and in the company`s periodic reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Contact:
Flamel Technologies S.A.
Dr. Gerard Soula, 33-4-72-78-34-34
soula@flamel.com
or
Stephen H. Willard, 202-862-8400
willard@flamel.com
--------------------------------------------------------------------------------
Source: Flamel Technologies S.A.
Die Aktie fällt seit einiger Zeit kontinuierlich, ist jemand bekannt, warum dies so ist?Lohnt es sich auf dem jetzigen Niveau einzusteigen?
Trading Spotlight
Flamel Tech mit deutlicher Ergebnissteigerung
12.03.2004
16:19
Die Aktien von Flamel Technologies steigen aktuell um fast 12% auf $26.03, nachdem das biopharmazeutische Unternehmen einen Gewinn von $1.9 Millionen oder 9 cents je Aktie für das abgelaufene vierte Quartal auswies. Der Umsatz lag bei $11.4 Millionen. Im Vorjahr verlor das Unternehmen noch $300,000 oder 2 cents je Aktie und generierte einen Umsatz von $5 Millionen. Analysten hatten im Vorfeld für das zurückliegende Quartal mit einem EPS von 4 cents gerechnet.
© BörseGo
12.03.2004
16:19
Die Aktien von Flamel Technologies steigen aktuell um fast 12% auf $26.03, nachdem das biopharmazeutische Unternehmen einen Gewinn von $1.9 Millionen oder 9 cents je Aktie für das abgelaufene vierte Quartal auswies. Der Umsatz lag bei $11.4 Millionen. Im Vorjahr verlor das Unternehmen noch $300,000 oder 2 cents je Aktie und generierte einen Umsatz von $5 Millionen. Analysten hatten im Vorfeld für das zurückliegende Quartal mit einem EPS von 4 cents gerechnet.
© BörseGo
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,02 | |
| +2,98 | |
| -0,47 | |
| +3,23 | |
| -9,09 | |
| -0,18 | |
| -1,06 | |
| +0,50 | |
| -2,91 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 88 | ||
| 58 | ||
| 48 | ||
| 35 | ||
| 22 | ||
| 21 | ||
| 21 | ||
| 18 | ||
| 14 | ||
| 13 |
